Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant [ID3969]
In development [GID-TA10852] Expected publication date: TBC
Search results
482 results
-
-
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [Review of TA611] [ID4069]
In development [GID-TA10985] Expected publication date: TBC
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
In development [GID-TA10979] Expected publication date: TBC
-
Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941
In development [GID-TA10832] Expected publication date: TBC
-
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]
In development [GID-TA10801] Expected publication date: TBC
-
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
In development [GID-TA10696] Expected publication date: TBC
-
Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]
In development [GID-TA10892] Expected publication date: TBC
-
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
In development [GID-TA10948] Expected publication date: TBC
-
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]
In development [GID-TA10785] Expected publication date: 16 November 2022
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
In development [GID-TA10763] Expected publication date: TBC
-
Gefapixant for treating refractory or unexplained chronic cough [ID3789]
In development [GID-TA10678] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) - lapatinib [ID20]
In development [GID-TAG387] Expected publication date: TBC
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Pacritinib for treating myelofibrosis [ID880]
In development [GID-TA10133] Expected publication date: TBC
-
Obesity - lorcaserin [ID337]
In development [GID-TAG420] Expected publication date: TBC
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622
In development [GID-TAG360] Expected publication date: TBC
-
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
In development [GID-TA10180] Expected publication date: TBC
-
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
In development [GID-TAG418] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
In development [GID-TA10165] Expected publication date: TBC
-
Prostate cancer (prevention) - dutasteride [ID75]
In development [GID-TAG409] Expected publication date: TBC
-
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: TBC
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Nivolumab with radiation therapy for untreated glioblastoma ID1562
In development [GID-TA10443] Expected publication date: TBC
-
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
In development [GID-TA10452] Expected publication date: TBC
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
In development [GID-TA10427] Expected publication date: TBC
-
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
In development [GID-TA10522] Expected publication date: TBC
-
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
In development [GID-TA10267] Expected publication date: TBC
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
In development [GID-TA10536] Expected publication date: TBC
-
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818
In development [GID-HST10040] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC
-
Osteoporosis (postmenopausal women) - abaloparatide [ID882]
In development [GID-TA10071] Expected publication date: TBC
-
Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]
In development [GID-TA10923] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Abicipar pegol for treating wet age-related macular degeneration ID1533
In development [GID-TA10511] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
In development [GID-TA10817] Expected publication date: 31 May 2023
-
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
In development [GID-TA10583] Expected publication date: TBC
-
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)
In development [GID-TA10179] Expected publication date: TBC
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]
In development [GID-TA10171] Expected publication date: TBC
-
Lifitegrast for treating dry eye disease [ID1229]
In development [GID-TA10196] Expected publication date: TBC
-
Atherothrombotic events - vorapaxar [ID616]
In development [GID-TAG493] Expected publication date: TBC
-
Heart failure (acute) - serelaxin [ID673]
In development [GID-TAG454] Expected publication date: TBC
-
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]
In development [GID-TAG431] Expected publication date: TBC